Euroopan unioni - englanti - EMA (European Medicines Agency)

accord healthcare s.l.u. - arsenic trioxide - leukemia, promyelocytic, acute - antineoplastic agents - arsenic trioxide is indicated for induction of remission, and consolidation in adult patients with:newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (apl) (white blood cell count, ≤ 10 x 103/μl) in combination with all-trans-retinoic acid (atra)relapsed/refractory acute promyelocytic leukaemia (apl)(previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the promyelocytic leukaemia/retinoic-acid-receptor-alpha (pml/rar-alpha) gene.the response rate of other acute myelogenous leukaemia subtypes to arsenic trioxide has not been examined.

Euroopan unioni - englanti - EMA (European Medicines Agency)

mylan ireland limited - arsenic trioxide - leukemia, promyelocytic, acute - antineoplastic agents - arsenic trioxide mylan is indicated for induction of remission, and consolidation in adult patients with:- newly diagnosed low to intermediate risk acute promyelocytic leukaemia (apl) (white blood cell count, ≤ 10 x 103/μl) in combination with all trans retinoic acid (atra)- relapsed/refractory acute promyelocytic leukaemia (apl) (previous treatment should have included a retinoid and chemotherapy)characterised by the presence of the t(15;17) translocation and/or the presence of the promyelocytic leukaemia/retinoic acid receptor alpha (pml/rar alpha) gene.the response rate of other acute myelogenous leukaemia subtypes to arsenic trioxide has not beenexamined.

Yhdistynyt kuningaskunta - englanti - MHRA (Medicines & Healthcare Products Regulatory Agency)

potassium 6.5mmol) effervescent tablets bpc 1968 (actavis uk ltd - potassium bicarbonate; potassium acid tartrate - effervescent tablet - 500mg ; 300mg

Israel - englanti - Ministry of Health

lapidot medical import and marketing ltd - potassium chloride - concentrate for solution for infusion - potassium chloride 14.9 g / 100 ml - potassium chloride - potassium chloride - treatment of potassium deficiency states when oral replacement is not feasable.

Yhdistynyt kuningaskunta - englanti - MHRA (Medicines & Healthcare Products Regulatory Agency)

potassium 13.3mmol/5ml) solution for infusion 5ml ampoules (martindale pharmaceuticals ltd - potassium chloride - solution for infusion - 200mg/1ml

Yhdistynyt kuningaskunta - englanti - MHRA (Medicines & Healthcare Products Regulatory Agency)

potassium 20mmol/10ml) solution for infusion 10ml ampoules (hameln pharma ltd - potassium chloride - solution for infusion - 150mg/1ml

Yhdistynyt kuningaskunta - englanti - MHRA (Medicines & Healthcare Products Regulatory Agency)

potassium 13.3mmol/5ml) solution for infusion 5ml ampoules (hameln pharma ltd - potassium chloride - solution for infusion - 200mg/1ml

Yhdistynyt kuningaskunta - englanti - MHRA (Medicines & Healthcare Products Regulatory Agency)

potassium 27mmol/10ml) solution for infusion 10ml ampoules (martindale pharmaceuticals ltd - potassium chloride - solution for infusion - 200mg/1ml

Yhdistynyt kuningaskunta - englanti - MHRA (Medicines & Healthcare Products Regulatory Agency)

potassium 20mmol/10ml) solution for infusion 10ml ampoules (advanz pharma - potassium chloride - solution for infusion - 150mg/1ml

Australia - englanti - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - arsenic trioxide, quantity: 10 mg - injection, concentrated - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - for the induction of remission and consolidation in patients with acute promyelocytic leukaemia (apl) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose apl is characterised by the presence of the t(15:17) translocation or pml/rar-alpha gene expression.,for the induction of remission and consolidation in patients with previously untreated acute promyelocytic leukaemia (apl) in combination with all-trans retinoic acid (atra) and/or chemotherapy and whose apl is characterised by the presence of the t(15:17) translocation or pml/rar-alpha gene expression.